Connor Clark & Lunn Investment Management Ltd. Purchases 60,460 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Connor Clark & Lunn Investment Management Ltd. raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2,286.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 63,104 shares of the medical equipment provider’s stock after purchasing an additional 60,460 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Lantheus were worth $6,159,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Townsquare Capital LLC raised its position in Lantheus by 24.7% in the first quarter. Townsquare Capital LLC now owns 15,449 shares of the medical equipment provider’s stock valued at $1,508,000 after purchasing an additional 3,063 shares during the last quarter. Ontario Teachers Pension Plan Board bought a new position in Lantheus in the first quarter valued at about $1,733,000. Intrust Bank NA raised its position in Lantheus by 2.9% in the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider’s stock valued at $431,000 after purchasing an additional 125 shares during the last quarter. Westfield Capital Management Co. LP raised its position in Lantheus by 2.2% in the first quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider’s stock valued at $155,101,000 after purchasing an additional 34,052 shares during the last quarter. Finally, Allianz SE raised its position in Lantheus by 103.4% in the first quarter. Allianz SE now owns 7,906 shares of the medical equipment provider’s stock valued at $772,000 after purchasing an additional 4,020 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on LNTH shares. Wall Street Zen upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. Mizuho dropped their target price on Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. Truist Financial set a $63.00 price objective on Lantheus and gave the stock a “hold” rating in a research report on Monday. B. Riley lowered their price objective on Lantheus from $122.00 to $109.00 and set a “buy” rating for the company in a research report on Monday, June 23rd. Finally, William Blair restated a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and an average target price of $105.50.

Lantheus Price Performance

Shares of LNTH opened at $53.90 on Wednesday. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. The company has a market capitalization of $3.66 billion, a price-to-earnings ratio of 14.34 and a beta of 0.14. The business has a 50-day moving average of $75.41 and a 200-day moving average of $86.26.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.08). The business had revenue of $378.05 million during the quarter, compared to the consensus estimate of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%. The company’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.80 earnings per share. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director directly owned 318,650 shares in the company, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.00% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.